Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

	Eugarri								
CORCEPT THE Form 4 October 07, 201	ERAPEUTICS INC								
								PPROVAL	
CUNIVI 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIO Washington, D.C. 20549						COMMISSION	OMB Number:	3235-0287	
Check this box if no longer subject to Section 16. SECURITIES STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES SECURITIES Expires: January 31 2005 Estimated average burden hours per									
(Print or Type Resp	ponses)								
1. Name and Addi Lo Steven	2. Issuer Name and Symbol CORCEPT THE [CORT]			-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) C/O CORCEP THERAPEUT COMMONWE	3. Date of Earliest Tr (Month/Day/Year) 10/06/2015	ransaction			Director 10% Owner X Officer (give title Other (specify below) below) VP Commercial Operations				
	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
MENLO PARK, CA 94025 Form filed by More than One Reporting Person									
(City)									
	. Transaction Date 2A. Dee Month/Day/Year) Executio any (Month/	med 3. on Date, if Transactic Code Day/Year) (Instr. 8)	3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) Year) (Instr. 8) (A) or Code V Amount (D) Price		· · · -		7. Nature of		
Common 1 stock	0/06/2015	S	50,000	D	\$ 3.76 (1)	58,333	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	S I I		Amo Unde Secur	le and unt of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		
Reporting Owners											
Reporti	ng Owner Nai	me / Address		Relat	ionships						
- F			Director 10% Owne	r Officer	•		Other				

VP Commercial Operations

Lo Steven C/O CORCEPT THERAPEUTICS 149 COMMONWEALTH DRIVE MENLO PARK, CA 94025

Signatures

/s/ Joseph K. Belanoff, CEO of Corcept Therapeutics Incorporated attorney-in-fact	10/07/2015
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Price shown is the average price. Price of the individual blocks sold ranged from \$3.70 to \$3.81 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.